40 results about "Monoclonal antibody production" patented technology

The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided is a method of prolonging the in vivo survival of transplanted cells for the treatment of a disease or pathological condition. The method includes increasing the activity of Bcl-2 in a population of cells and transplanting the population of cells having increased Bcl-2 activity into a subject. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. A method to enhance the sensitivity of malignant cells to therapy is provided that includes decreasing the activity of Bcl-2 in the malignant cells. Methods to identify compounds that alter apoptotic cell death and to enhance monoclonal antibody production are also provided by the invention disclosed herein.

The present invention relates to anti-human NKX3.1 monoclonal antibody and its preparation method and application. The invention provides an anti-human NKX3.1 monoclonal antibody, and further provides the amino acid sequences of the variable regions of its heavy chain and light chain. On this basis, the antibody can be prepared by conventional genetic engineering methods. Compared with the traditional monoclonal antibody preparation method, the anti-human NKX3.1 recombinant antibody prepared by the genetic engineering method of the present invention has the advantages of known sequence, stable antibody properties, good repeatability, etc., and can specifically recognize human NKX3.1 protein , can be used for IHC immunohistochemical detection. And the standardized antibody production process avoids the risk factors that appear in the traditional monoclonal antibody production and storage process. Furthermore, on the basis of the amino acid sequence of the antibody provided by the present invention, one or more amino acid additions, deletions, substitutions, etc., can also be modified to obtain active fragments or conservative variants, in order to further improve the specificity and Affinity lays the groundwork.